Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Rankning i aktier #3977
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aktiekurs
$32.88
Senast synkroniserad: 2026-10-20
Marknadsvärde
$4.13B
Förändring (1 dag)
3.11%
Förändring (1 år)
59.32%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)

Kategori

Healthcare
Historik för aktiesplit för Arcutis Biotherapeutics, Inc. (ARQT)
Aktien Arcutis Biotherapeutics, Inc. (symbol: ARQT) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En ARQT-aktie köpt före Oct 21, 2026 motsvarar nu 0 ARQT-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
Inte tillräckligt med data för de angivna datumen.
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL